[ad_1]
The German government is “keen to enter into discussions” with the new US administration to agree on changes to US policy that prioritizes the supply of local coronavirus vaccine to US production facilities, according to a document from the German Ministry of Health.
In a lengthy document released Tuesday that answered questions from the German Social Democrats, the Health Department explains why the United States was able to secure an additional supply of BioNTech / Pfizer vaccines on specific dates as the increase in the The EU’s offer should come in. 2021. ”
The Department of Health says an executive order from the US President meant that production facilities in the country were “encouraged to initially make the vaccine available to the United States.” This means that the European production sites for the BioNTech / Pfizer vaccine, as well as the Moderna vaccine, must supply the rest of the world, in addition to Europe.
“Businesses as well as the federal government wish to enter into discussions with the new American administration in order to achieve adjustments,” wrote the Department of Health.
The document also discussed Germany’s bilateral deal with BioNTech / Pfizer – something the Commission has let Germany off the hook for, although it seems to run counter to the efforts of the European Union to develop a unified vaccine strategy.
The problem, the health ministry explained, is the funding that BioNTech has received from the German ministry of education and research. This money meant that BioNTech had to supply part of the vaccines to Germany. As a result, the health ministry had to issue a pre-contractual letter of intent in the form of a memorandum of understanding on September 8 for an additional 30 million doses of the vaccine, the health ministry wrote.
[ad_2]
Source link